Abstract
Summary
Migraines are a family of recurrent attacks.The symptom is paroxysmal unilateral throbbing headache, accompanied by nausea, vomiting and confusion. Migraine therapeutics includes triptans, acetylcholine inhibitors/neurotoxins, ergot alkaloids, nsaids, ditan, CGRP small molecule antagonists, CGRP monoclonal antibodies, etc.
LPI (LP Information)' newest research report, the “Migraine Therapeutics Industry Forecast” looks at past sales and reviews total world Migraine Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Migraine Therapeutics sales for 2023 through 2029. With Migraine Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Migraine Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Migraine Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Migraine Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Migraine Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Migraine Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Migraine Therapeutics.
The global Migraine Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Migraine Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Migraine Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Migraine Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Migraine Therapeutics players cover Allergan, Merck, Pfizer, Teva, Amgen, Johnson & Johnson, Endo International, GlaxoSmithKline and Impax, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Migraine Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Specific Anti-migraine Drugs
Acute Therapies
Preventative Therapies
Other
Segmentation by application
Hospitals
Clinics
Household Use
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Merck
Pfizer
Teva
Amgen
Johnson & Johnson
Endo International
GlaxoSmithKline
Impax
Abbott
Bayer
Eli Lilly
Novartis International
Ethypharm
Kowa Pharmaceuticals America
Winston Pharmaceuticals
AstraZeneca
Amirall
OptiNose
Revance Therapeutics
RedHill Biopharma
Bausch Health
NeurAxon
Biohaven Pharma
Eisai
Valeant Pharma
LPI (LP Information)' newest research report, the “Migraine Therapeutics Industry Forecast” looks at past sales and reviews total world Migraine Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Migraine Therapeutics sales for 2023 through 2029. With Migraine Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Migraine Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Migraine Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Migraine Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Migraine Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Migraine Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Migraine Therapeutics.
The global Migraine Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Migraine Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Migraine Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Migraine Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Migraine Therapeutics players cover Allergan, Merck, Pfizer, Teva, Amgen, Johnson & Johnson, Endo International, GlaxoSmithKline and Impax, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Migraine Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Specific Anti-migraine Drugs
Acute Therapies
Preventative Therapies
Other
Segmentation by application
Hospitals
Clinics
Household Use
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Merck
Pfizer
Teva
Amgen
Johnson & Johnson
Endo International
GlaxoSmithKline
Impax
Abbott
Bayer
Eli Lilly
Novartis International
Ethypharm
Kowa Pharmaceuticals America
Winston Pharmaceuticals
AstraZeneca
Amirall
OptiNose
Revance Therapeutics
RedHill Biopharma
Bausch Health
NeurAxon
Biohaven Pharma
Eisai
Valeant Pharma
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Migraine Therapeutics Market Size 2018-2029
2.1.2 Migraine Therapeutics Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Migraine Therapeutics Segment by Type
2.2.1 Specific Anti-migraine Drugs
2.2.2 Acute Therapies
2.2.3 Preventative Therapies
2.2.4 Other
2.3 Migraine Therapeutics Market Size by Type
2.3.1 Migraine Therapeutics Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Migraine Therapeutics Market Size Market Share by Type (2018-2023)
2.4 Migraine Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Household Use
2.4.4 Others
2.5 Migraine Therapeutics Market Size by Application
2.5.1 Migraine Therapeutics Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Migraine Therapeutics Market Size Market Share by Application (2018-2023)
3 Migraine Therapeutics Market Size by Player
3.1 Migraine Therapeutics Market Size Market Share by Players
3.1.1 Global Migraine Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Migraine Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Migraine Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Migraine Therapeutics by Regions
4.1 Migraine Therapeutics Market Size by Regions (2018-2023)
4.2 Americas Migraine Therapeutics Market Size Growth (2018-2023)
4.3 APAC Migraine Therapeutics Market Size Growth (2018-2023)
4.4 Europe Migraine Therapeutics Market Size Growth (2018-2023)
4.5 Middle East & Africa Migraine Therapeutics Market Size Growth (2018-2023)
5 Americas
5.1 Americas Migraine Therapeutics Market Size by Country (2018-2023)
5.2 Americas Migraine Therapeutics Market Size by Type (2018-2023)
5.3 Americas Migraine Therapeutics Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Migraine Therapeutics Market Size by Region (2018-2023)
6.2 APAC Migraine Therapeutics Market Size by Type (2018-2023)
6.3 APAC Migraine Therapeutics Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Migraine Therapeutics by Country (2018-2023)
7.2 Europe Migraine Therapeutics Market Size by Type (2018-2023)
7.3 Europe Migraine Therapeutics Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Migraine Therapeutics by Region (2018-2023)
8.2 Middle East & Africa Migraine Therapeutics Market Size by Type (2018-2023)
8.3 Middle East & Africa Migraine Therapeutics Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Migraine Therapeutics Market Forecast
10.1 Global Migraine Therapeutics Forecast by Regions (2024-2029)
10.1.1 Global Migraine Therapeutics Forecast by Regions (2024-2029)
10.1.2 Americas Migraine Therapeutics Forecast
10.1.3 APAC Migraine Therapeutics Forecast
10.1.4 Europe Migraine Therapeutics Forecast
10.1.5 Middle East & Africa Migraine Therapeutics Forecast
10.2 Americas Migraine Therapeutics Forecast by Country (2024-2029)
10.2.1 United States Migraine Therapeutics Market Forecast
10.2.2 Canada Migraine Therapeutics Market Forecast
10.2.3 Mexico Migraine Therapeutics Market Forecast
10.2.4 Brazil Migraine Therapeutics Market Forecast
10.3 APAC Migraine Therapeutics Forecast by Region (2024-2029)
10.3.1 China Migraine Therapeutics Market Forecast
10.3.2 Japan Migraine Therapeutics Market Forecast
10.3.3 Korea Migraine Therapeutics Market Forecast
10.3.4 Southeast Asia Migraine Therapeutics Market Forecast
10.3.5 India Migraine Therapeutics Market Forecast
10.3.6 Australia Migraine Therapeutics Market Forecast
10.4 Europe Migraine Therapeutics Forecast by Country (2024-2029)
10.4.1 Germany Migraine Therapeutics Market Forecast
10.4.2 France Migraine Therapeutics Market Forecast
10.4.3 UK Migraine Therapeutics Market Forecast
10.4.4 Italy Migraine Therapeutics Market Forecast
10.4.5 Russia Migraine Therapeutics Market Forecast
10.5 Middle East & Africa Migraine Therapeutics Forecast by Region (2024-2029)
10.5.1 Egypt Migraine Therapeutics Market Forecast
10.5.2 South Africa Migraine Therapeutics Market Forecast
10.5.3 Israel Migraine Therapeutics Market Forecast
10.5.4 Turkey Migraine Therapeutics Market Forecast
10.5.5 GCC Countries Migraine Therapeutics Market Forecast
10.6 Global Migraine Therapeutics Forecast by Type (2024-2029)
10.7 Global Migraine Therapeutics Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Allergan
11.1.1 Allergan Company Information
11.1.2 Allergan Migraine Therapeutics Product Offered
11.1.3 Allergan Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Allergan Main Business Overview
11.1.5 Allergan Latest Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Migraine Therapeutics Product Offered
11.2.3 Merck Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Merck Main Business Overview
11.2.5 Merck Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Migraine Therapeutics Product Offered
11.3.3 Pfizer Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Teva
11.4.1 Teva Company Information
11.4.2 Teva Migraine Therapeutics Product Offered
11.4.3 Teva Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Teva Main Business Overview
11.4.5 Teva Latest Developments
11.5 Amgen
11.5.1 Amgen Company Information
11.5.2 Amgen Migraine Therapeutics Product Offered
11.5.3 Amgen Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Amgen Main Business Overview
11.5.5 Amgen Latest Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Information
11.6.2 Johnson & Johnson Migraine Therapeutics Product Offered
11.6.3 Johnson & Johnson Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Johnson & Johnson Main Business Overview
11.6.5 Johnson & Johnson Latest Developments
11.7 Endo International
11.7.1 Endo International Company Information
11.7.2 Endo International Migraine Therapeutics Product Offered
11.7.3 Endo International Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Endo International Main Business Overview
11.7.5 Endo International Latest Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Information
11.8.2 GlaxoSmithKline Migraine Therapeutics Product Offered
11.8.3 GlaxoSmithKline Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 GlaxoSmithKline Main Business Overview
11.8.5 GlaxoSmithKline Latest Developments
11.9 Impax
11.9.1 Impax Company Information
11.9.2 Impax Migraine Therapeutics Product Offered
11.9.3 Impax Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Impax Main Business Overview
11.9.5 Impax Latest Developments
11.10 Abbott
11.10.1 Abbott Company Information
11.10.2 Abbott Migraine Therapeutics Product Offered
11.10.3 Abbott Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Abbott Main Business Overview
11.10.5 Abbott Latest Developments
11.11 Bayer
11.11.1 Bayer Company Information
11.11.2 Bayer Migraine Therapeutics Product Offered
11.11.3 Bayer Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Bayer Main Business Overview
11.11.5 Bayer Latest Developments
11.12 Eli Lilly
11.12.1 Eli Lilly Company Information
11.12.2 Eli Lilly Migraine Therapeutics Product Offered
11.12.3 Eli Lilly Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Eli Lilly Main Business Overview
11.12.5 Eli Lilly Latest Developments
11.13 Novartis International
11.13.1 Novartis International Company Information
11.13.2 Novartis International Migraine Therapeutics Product Offered
11.13.3 Novartis International Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Novartis International Main Business Overview
11.13.5 Novartis International Latest Developments
11.14 Ethypharm
11.14.1 Ethypharm Company Information
11.14.2 Ethypharm Migraine Therapeutics Product Offered
11.14.3 Ethypharm Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Ethypharm Main Business Overview
11.14.5 Ethypharm Latest Developments
11.15 Kowa Pharmaceuticals America
11.15.1 Kowa Pharmaceuticals America Company Information
11.15.2 Kowa Pharmaceuticals America Migraine Therapeutics Product Offered
11.15.3 Kowa Pharmaceuticals America Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Kowa Pharmaceuticals America Main Business Overview
11.15.5 Kowa Pharmaceuticals America Latest Developments
11.16 Winston Pharmaceuticals
11.16.1 Winston Pharmaceuticals Company Information
11.16.2 Winston Pharmaceuticals Migraine Therapeutics Product Offered
11.16.3 Winston Pharmaceuticals Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Winston Pharmaceuticals Main Business Overview
11.16.5 Winston Pharmaceuticals Latest Developments
11.17 AstraZeneca
11.17.1 AstraZeneca Company Information
11.17.2 AstraZeneca Migraine Therapeutics Product Offered
11.17.3 AstraZeneca Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 AstraZeneca Main Business Overview
11.17.5 AstraZeneca Latest Developments
11.18 Amirall
11.18.1 Amirall Company Information
11.18.2 Amirall Migraine Therapeutics Product Offered
11.18.3 Amirall Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Amirall Main Business Overview
11.18.5 Amirall Latest Developments
11.19 OptiNose
11.19.1 OptiNose Company Information
11.19.2 OptiNose Migraine Therapeutics Product Offered
11.19.3 OptiNose Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 OptiNose Main Business Overview
11.19.5 OptiNose Latest Developments
11.20 Revance Therapeutics
11.20.1 Revance Therapeutics Company Information
11.20.2 Revance Therapeutics Migraine Therapeutics Product Offered
11.20.3 Revance Therapeutics Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Revance Therapeutics Main Business Overview
11.20.5 Revance Therapeutics Latest Developments
11.21 RedHill Biopharma
11.21.1 RedHill Biopharma Company Information
11.21.2 RedHill Biopharma Migraine Therapeutics Product Offered
11.21.3 RedHill Biopharma Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 RedHill Biopharma Main Business Overview
11.21.5 RedHill Biopharma Latest Developments
11.22 Bausch Health
11.22.1 Bausch Health Company Information
11.22.2 Bausch Health Migraine Therapeutics Product Offered
11.22.3 Bausch Health Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Bausch Health Main Business Overview
11.22.5 Bausch Health Latest Developments
11.23 NeurAxon
11.23.1 NeurAxon Company Information
11.23.2 NeurAxon Migraine Therapeutics Product Offered
11.23.3 NeurAxon Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 NeurAxon Main Business Overview
11.23.5 NeurAxon Latest Developments
11.24 Biohaven Pharma
11.24.1 Biohaven Pharma Company Information
11.24.2 Biohaven Pharma Migraine Therapeutics Product Offered
11.24.3 Biohaven Pharma Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 Biohaven Pharma Main Business Overview
11.24.5 Biohaven Pharma Latest Developments
11.25 Eisai
11.25.1 Eisai Company Information
11.25.2 Eisai Migraine Therapeutics Product Offered
11.25.3 Eisai Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Eisai Main Business Overview
11.25.5 Eisai Latest Developments
11.26 Valeant Pharma
11.26.1 Valeant Pharma Company Information
11.26.2 Valeant Pharma Migraine Therapeutics Product Offered
11.26.3 Valeant Pharma Migraine Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.26.4 Valeant Pharma Main Business Overview
11.26.5 Valeant Pharma Latest Developments
12 Research Findings and Conclusion